ME Therapeutics Holdings, Inc. (TSE:METX) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ME Therapeutics Holdings Inc. has announced a strategic partnership with NanoVation Therapeutics to develop mRNA-based cancer therapies targeting myeloid cells, utilizing NanoVation’s advanced lipid nanoparticle technologies. The collaboration will focus on testing the delivery and efficacy of these therapies in a preclinical mouse model, with the potential to fast-track new cancer treatments. This initiative combines ME Therapeutics’ expertise in immuno-oncology with NanoVation Therapeutics’ leading RNA delivery technology.
For further insights into TSE:METX stock, check out TipRanks’ Stock Analysis page.